Key facts
- It has raised $345.0M across 5 recorded rounds; the latest was PIPE ($105.0M) in Nov 2024.
- 6 institutional filers report fund marks on Cidara Therapeutics across 18 filings.
- Cidara Therapeutics has filed 5 Form Ds with the SEC since 2015, most recently May 2024 ($240.0M sold to 7 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 5 rounds
- ·Watchlist + deal alerts for Cidara Therapeutics
Create free account
No card required
Funding rounds
5 roundsNov 2024PIPE$105.0M▮
Apr 2024PIPE$240.0M▮
About Cidara Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Cidara Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Cidara Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
6 filers · latest Nov 20256 SEC-registered funds reported 18 fair-value marks on Cidara Therapeutics between Jul 2025 and Nov 2025. Filer-level marks and implied $/share are available to Pro members.